DE202005012984U1 - Oral combination, useful in the treatment and/or prophylaxis of eye diseases e.g. glaucoma, comprises one or more dosage units comprising e.g. zinc oxide; highly purified fish oil; ascorbic acid and optionally carotenoid, cinnamon - Google Patents
Oral combination, useful in the treatment and/or prophylaxis of eye diseases e.g. glaucoma, comprises one or more dosage units comprising e.g. zinc oxide; highly purified fish oil; ascorbic acid and optionally carotenoid, cinnamon Download PDFInfo
- Publication number
- DE202005012984U1 DE202005012984U1 DE202005012984U DE202005012984U DE202005012984U1 DE 202005012984 U1 DE202005012984 U1 DE 202005012984U1 DE 202005012984 U DE202005012984 U DE 202005012984U DE 202005012984 U DE202005012984 U DE 202005012984U DE 202005012984 U1 DE202005012984 U1 DE 202005012984U1
- Authority
- DE
- Germany
- Prior art keywords
- dosage unit
- dosage
- dosage units
- zinc oxide
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 title claims abstract description 52
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 44
- 235000021466 carotenoid Nutrition 0.000 title claims abstract description 30
- 150000001747 carotenoids Chemical class 0.000 title claims abstract description 30
- 239000011787 zinc oxide Substances 0.000 title claims abstract description 23
- 235000010323 ascorbic acid Nutrition 0.000 title claims abstract description 17
- 239000011668 ascorbic acid Substances 0.000 title claims abstract description 17
- 229960005070 ascorbic acid Drugs 0.000 title claims abstract description 17
- 235000021323 fish oil Nutrition 0.000 title claims abstract description 16
- 208000010412 Glaucoma Diseases 0.000 title description 6
- 208000030533 eye disease Diseases 0.000 title description 6
- 238000011282 treatment Methods 0.000 title description 6
- 238000011321 prophylaxis Methods 0.000 title description 5
- 235000017803 cinnamon Nutrition 0.000 title description 2
- 241000723347 Cinnamomum Species 0.000 title 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 67
- 235000012680 lutein Nutrition 0.000 claims abstract description 35
- 229960005375 lutein Drugs 0.000 claims abstract description 35
- 239000001656 lutein Substances 0.000 claims abstract description 35
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 35
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 35
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 35
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 24
- 239000005751 Copper oxide Substances 0.000 claims abstract description 20
- 229910000431 copper oxide Inorganic materials 0.000 claims abstract description 20
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000010208 anthocyanin Nutrition 0.000 claims abstract description 19
- 239000004410 anthocyanin Substances 0.000 claims abstract description 19
- 229930002877 anthocyanin Natural products 0.000 claims abstract description 19
- 150000004636 anthocyanins Chemical class 0.000 claims abstract description 19
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 18
- 239000011720 vitamin B Substances 0.000 claims abstract description 18
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 17
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 17
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 17
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 14
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 14
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 13
- 235000020230 cinnamon extract Nutrition 0.000 claims abstract description 13
- 229940046001 vitamin b complex Drugs 0.000 claims abstract description 13
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 12
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 12
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 11
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 11
- 239000001751 lycopene Substances 0.000 claims abstract description 11
- 235000012661 lycopene Nutrition 0.000 claims abstract description 11
- 229960004999 lycopene Drugs 0.000 claims abstract description 11
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 11
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 11
- 239000002151 riboflavin Substances 0.000 claims abstract description 11
- 229960002477 riboflavin Drugs 0.000 claims abstract description 11
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 11
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 9
- 241000208829 Sambucus Species 0.000 claims abstract description 8
- 235000018735 Sambucus canadensis Nutrition 0.000 claims abstract description 8
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 8
- 240000006365 Vitis vinifera Species 0.000 claims abstract description 8
- 235000007123 blue elder Nutrition 0.000 claims abstract description 8
- 235000007124 elderberry Nutrition 0.000 claims abstract description 8
- 235000008995 european elder Nutrition 0.000 claims abstract description 8
- 235000020095 red wine Nutrition 0.000 claims abstract description 8
- 235000005911 diet Nutrition 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 32
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 32
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 32
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 32
- 235000010930 zeaxanthin Nutrition 0.000 claims description 32
- 239000001775 zeaxanthin Substances 0.000 claims description 32
- 229940043269 zeaxanthin Drugs 0.000 claims description 32
- 229940093797 bioflavonoids Drugs 0.000 claims description 17
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 13
- 239000006014 omega-3 oil Substances 0.000 claims description 11
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 6
- 235000021014 blueberries Nutrition 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000006286 aqueous extract Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229960004643 cupric oxide Drugs 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229960001296 zinc oxide Drugs 0.000 claims description 2
- 235000014692 zinc oxide Nutrition 0.000 claims description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims 3
- -1 zeaxanthene Chemical compound 0.000 abstract description 9
- 244000078534 Vaccinium myrtillus Species 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract description 4
- 230000037213 diet Effects 0.000 abstract description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 description 22
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 18
- 208000002177 Cataract Diseases 0.000 description 16
- 230000002980 postoperative effect Effects 0.000 description 11
- 206010025421 Macule Diseases 0.000 description 10
- 206010064930 age-related macular degeneration Diseases 0.000 description 10
- 210000001508 eye Anatomy 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- 235000016804 zinc Nutrition 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 235000013734 beta-carotene Nutrition 0.000 description 6
- 239000011648 beta-carotene Substances 0.000 description 6
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 6
- 229960002747 betacarotene Drugs 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940045997 vitamin a Drugs 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002066 eicosanoids Chemical class 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 240000006028 Sambucus nigra Species 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003595 thromboxanes Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PDRZOMUQUZBNKV-MKOSUFFBSA-N [(2e,4e,6z,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] dihydrogen phosphate Chemical compound OP(=O)(O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C PDRZOMUQUZBNKV-MKOSUFFBSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000011678 thiamine pyrophosphate Substances 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Die Erfindung betrifft neue Kombinationen zur gleichzeitigen oder sequentiellen oralen Verabreichung umfassend mehrere Komponenten in Form eines Arzneimittels, Diätetikums, Nahrungs- oder Nahrungsergänzungsmittels. Die Komponenten umfassen Dosierungseinheiten, die d-α Tocopherolacetat, Zinkoxid, Kupferoxid, hochreines Fischöl, Ascorbinsäure, Carotinoide, Vitamin B Komplex, Bioflavonoide, Anthocyane und Zimtextrakt enthalten. Die erfindungsgemäßen Kombinationen ermöglichen eine maßgeschneiderte, individuelle Therapie von Augenerkrankungen, wie (altersbedingte) Makuladegeneration (AMD), Glaukom (grüner Star), Katarakt (grauer Star), diabetische Rethinopathie und trockenes Auge. Zusätzlich ermöglicht die prä- und postoperative Gabe von Lutein und/oder Zeaxanthin bei Linsenentfernung, wie bei einer Katarakt-Operation einen effektiven Schutz der Makula vor Ausbildung einer postoperativen Makuladegeneration. Folglich sind Lutein und/oder Zeaxanthin geeignet zur Prophylaxe und Therapie einer postoperativen Makuladegeneration, welche durch Linsenentfernung, insbesondere bei der Katarakt-Operation hervorgerufen wird.The The invention relates to novel combinations for simultaneous or sequential oral administration comprising several components in the form of a Medicine, dietetics, Food or dietary supplement. The components comprise dosage units containing d-α tocopherol acetate, zinc oxide, Copper oxide, high purity fish oil, ascorbic acid, Carotenoids, vitamin B complex, bioflavonoids, anthocyanins and cinnamon extract contain. The combinations according to the invention enable a tailor made, individual therapy of eye diseases, such as (age-related) Macular degeneration (AMD), glaucoma (cataract), cataract (gray Star), diabetic retinopathy and dry eye. In addition, the pre- and postoperative administration of lutein and / or zeaxanthin in lens removal, as in a cataract surgery, effective protection of the macula before the development of a postoperative macular degeneration. Consequently are Lutein and / or zeaxanthin suitable for prophylaxis and therapy a postoperative macular degeneration caused by lens removal, especially in cataract surgery is caused.
Das Vitamin d-α Tocopherolacetat (Vitamin E) schützt in seiner Funktion als Antioxidans Zellmembranen, insbesondere die mehrfach ungesättigten Fettsäuren in den Lipiden dieser Membranen, vor dem zerstörerischen Einfluss des molekularen Sauerstoffs (Sauerstoffradikal). Diese Sauerstoffverbindungen spielen bei der Entstehung verschiedener Krankheiten, wie z. B. Grauer Star (Katarakt), Arteriosklerose und Krebs eine Rolle.The Vitamin d-α tocopherol acetate (Vitamin E) protects in its function as an antioxidant cell membranes, in particular the polyunsaturated fatty acids in the lipids of these membranes, before the destructive influence of the molecular Oxygen (oxygen radical). These oxygen compounds play in the development of various diseases, such. B. cataract (Cataract), atherosclerosis and cancer play a role.
Der Vitamin B Komplex bezeichnet einen Komplex aus mehreren schwer voneinander trennbaren Wirkstoffen, typischerweise bekannt als Vitamin B1 (Thiamin), B2 (Riboflavin), B3 (Nikotinsäure/Niacin), B5 (Calcium Panthothenat), B6, B12 (Cobalamin) und B15. Alle B-Vitamine sind wichtige Regulatoren im Kohlehydrat-, Fett- und Eiweißstoffwechsel. Sie sind zudem wichtig für die Blutbildung, außerdem fungieren sie auch als Antioxidantien. So ist z.B. Vitamin B1 besonders wichtig für den Kohlehydratstoffwechsel von Nerven, Gehirn und Muskeln, Vitamin B2 für die Umwandlung von Fetten, Eiweißen und Kohlehydraten in Nährstoffe und die Vitamine B3, B5, B6 und B12 für Stoffwechselvorgänge. Ein Vitamin B2-Mangel wird z.B. mit brennenden, juckenden Augen und Lichtempfindlichkeit in Zusammenhang gebracht.The vitamin B complex refers to a complex of several difficult to separate active ingredients, typically known as vitamin B 1 (thiamine), B 2 (riboflavin), B 3 (nicotinic acid / niacin), B 5 (calcium pantothenate), B 6 , B 12 (Cobalamin) and B 15 . All B vitamins are important regulators in carbohydrate, fat and protein metabolism. They are also important for the formation of blood and also act as antioxidants. For example, vitamin B 1 is particularly important for the carbohydrate metabolism of nerves, brain and muscles, vitamin B 2 for the conversion of fats, proteins and carbohydrates into nutrients and vitamins B 3 , B 5 , B 6 and B 12 for metabolic processes. A vitamin B 2 deficiency is associated with, for example, burning, itchy eyes and photosensitivity.
Ascorbinsäure (Vitamin C) ist ein Radikalfänger und hat eine antioxidative Wirkung. Ascorbinsäure ist ein wichtiger Cofaktor bei der Hydroxylierungsreaktion und steuert damit die körpereigene Herstellung von Collagen. Es spielt darüber hinaus eine wichtige Rolle beim Aufbau von Aminosäuren. Ein Vitamin-C-Mangel wird mit der Entstehung einer altersbedingten Makuladegeneration in Zusammenhang gebracht.Ascorbic acid (vitamin C) is a radical scavenger and has an antioxidant effect. Ascorbic acid is an important cofactor in the hydroxylation reaction and thus controls the body's own Production of collages. It also plays an important role in the construction of amino acids. A vitamin C deficiency becomes associated with the onset of age Associated with macular degeneration.
Aus der Stoffgruppe der Carotinoide sind neben dem β-Carotin, vor allem Lycopin, Lutein und Zeaxanthin im menschlichen Gewebe nachweisbar und von physiologischer Bedeutung. Neben ihrem Vitamin Charakter besitzen die Carotinoide wichtige Eigenschaften als Antioxidantien, wobei das Lycopin aufgrund seiner hohen Anzahl an konjungierten Doppelbindungen ein ca. 1,5-fach stärkeres antioxidatives Potential aufweist.Out the substance group of the carotenoids are in addition to the β-carotene, especially lycopene, Lutein and zeaxanthin are detectable in human tissue and from physiological significance. In addition to possessing their vitamin character the carotenoids have important properties as antioxidants, being lycopene due to its high number of conjugated double bonds a 1.5 times stronger has antioxidant potential.
β-Carotin besitzt einen Provitamincharakter und kann deshalb zu Vitamin A umgewandelt werden. Vitamin A ist wichtig für den Sehvorgang, besonders für die Nachtsichtigkeit. Ein Mangel an Vitamin A kann außerdem zu weiteren Veränderungen und Krankheiten des Auges führen. Symptome können ein Austrocknen der Bindehaut des Auges sein, angeschwollene Lider und Geschwüre, die sich auf der Hornhaut bilden, was unbehandelt zur Blindheit führen kann. Vitamin-A-Mangel soll auch bei der Entstehung des Grauen Stars (Katarakt) und der altersbedingten Makuladegeneration (AMD) eine Rolle spielen.β-carotene has a provitamin character and can therefore to vitamin A. being transformed. Vitamin A is important for the vision, especially for the Night vision. A lack of vitamin A may also increase further changes and diseases of the eye. Symptoms can be Dry out the conjunctiva of the eye, swollen eyelids and ulcers, which form on the cornea, untreated to blindness to lead can. Vitamin A deficiency is also said to be involved in the onset of cataracts (Cataract) and age-related macular degeneration (AMD) Role-play.
Lutein und Zeaxanthin besitzen im Gegensatz zu dem ß-Carotin nur eine geringe Vitamin A-Aktivität.lutein and zeaxanthin have little, in contrast to the ß-carotene Vitamin A activity.
Die verschiedenen Carotinoide reichern sich in bestimmten Geweben und Organen bevorzugt an. So reichern sich Lutein und Zeaxanthin bevorzugt in der Macula des Auges an. Dort absorbieren sie das kurzwellige, energiereiche Licht und schützen so das Auge vor der Schädigung durch freie Radikale. Erfindungsgemäß ist dies insbesondere nach Linsenentfernung, wie zum Beispiel der Katarakt-Operation, sowie Eingriffen aller Art im hinteren Augenabschnitt bedeutsam.The different carotenoids accumulate in certain tissues and Organs preferred. Lutein and zeaxanthin accumulate preferentially in the macula of the eye. There they absorb the short-wave, high energy light and protect so the eye from the injury by free radicals. According to the invention this is especially after Lens removal, such as the cataract surgery, as well Interventions of all kinds in the posterior segment significant.
Erfindungsgemäß stellte sich ferner heraus, dass insbesondere Lutein und/oder Zeaxanthin einen verbesserten prä- und postoperativen Schutz der Makula bei Patienten mit Linsenentfernung bieten. So eignen sich Lutein und/oder Zeaxanthin erfindungsgemäß zur Therapie und Prophylaxe der durch Linsenentfernung induzierten Makuladegeneration. Die prophylaktische als auch therapeutische Wirkung zeigte sich bei einer Dosierung von 1 bis 100 mg, bevorzugt bei 1 bis 50 mg, stärker bevorzugt bei 10 bis 30 mg Lutein und/oder Zeaxanthin. Hintergrund dessen ist die Gefahr der Schädigung der Makula durch Licht, insbesondere durch Licht blauer Wellenlänge, das durch die implantierten Kunstlinse nicht im selben Umfang gefiltert wird, wie dies die natürliche Linse vermag. Lutein und Zeaxanthin lagern sich bevorzugt in der Makula ein, und resorbieren dort die schädigende Strahlung. Zur Erreichung dieses Effekts ist es entscheidend Lutein und/oder Zeaxanthin unmittelbar vor der Linsenentfernung hochdosiert, d.h. in einer Dosierung von 1 bis 100 mg/d, bevorzugt 10 bis 40 mg/d einzunehmen, um eine rasche Anreicherung in der Makula zu erreichen. Danach sind zum Schutz der Makula Erhaltungsdosen zwischen 10 und 20 mg/d, stärker bevorzugt zwischen 5 und 10 mg/d nötig.According to the invention, it has also been found that, in particular, lutein and / or zeaxanthin offer improved pre- and postoperative protection of the macula in patients with lens removal. Thus, lutein and / or zeaxanthin according to the invention are suitable for the therapy and prophylaxis of the lens removal induced macular degeneration. The prophylactic as well as therapeutic effect was found at a dosage of 1 to 100 mg, preferably 1 to 50 mg, more preferably 10 to 30 mg lutein and / or zeaxanthin. Background of this is the risk of damage to the macula by light, in particular by light of blue wavelength, which is not filtered by the implanted artificial lens to the same extent as the natural lens is capable of. Lutein and zeaxanthin prefer to accumulate in the macula, and resorb there the schä Dying radiation. To achieve this effect, it is crucial to high-dose lutein and / or zeaxanthin immediately before lens removal, ie at a dosage of 1 to 100 mg / d, preferably 10 to 40 mg / d, to achieve rapid accumulation in the macula. Thereafter, to protect the macula, maintenance doses between 10 and 20 mg / d, more preferably between 5 and 10 mg / d are needed.
Lycopin und ß-Carotin dagegen können das unkontrollierte Zellwachstum regulieren, indem sie den interzellulären Informationsaustausch über „gap junctions" wieder reaktivieren.lycopene and β-carotene against it can Regulate uncontrolled cell growth by reactivating intercellular information exchange via gap junctions.
Bioflavonoide wirken als Antioxidantien und können somit das Auge vor freien Radikalen schützen. Zudem hemmen sie die Ausschüttung von Histamin im Körper und wirken so als natürliche Antihistaminika. Ferner haben sie eine begünstigende Wirkung bei Bluthochdruck und Durchblutungsstörungen.bioflavonoids act as antioxidants and can thus protecting the eye from free radicals. In addition, they inhibit the distribution of histamine in the body and act as natural Antihistamines. Furthermore, they have a beneficial effect on hypertension and circulatory disorders.
Anthocyane sind stark wirkende Antioxidantien. Sie sollen die Zellatmung verbessern, Darmkrebs und Ablagerungen von LDL-Cholesterin in den Gefäßen verhindern und vor Herz-Kreislauf-Erkrankungen schützen. Insbesondere sollen Anthocyane gewonnen aus den Holunder- und Heidelbeeren sowie Rotweintraube das nächtliche Sehen verbessern und den Cholesterinspiegel senken.anthocyanins are powerful antioxidants. They should improve cell respiration, Prevent colon cancer and deposits of LDL cholesterol in the blood vessels and protect against cardiovascular disease. In particular, anthocyanins obtained from elderberry and bilberry as well as red wine grape the nocturnal See to improve vision and lower cholesterol.
Fischöl, insbesondere Ω-3-Fettsäuren sind dafür bekannt, die Funktion des Immunsystems zu verbessern, rheumatischen Beschwerden und Hautleiden entgegenzuwirken und die Entstehung der Arteriosklerose zu verhindern bzw. zu verlangsamen. Ω-3-Fettsäuren stellen wie Ω-6-Fettsäuren wichtige Ausgangsstoffe für die Bildung der Eicosapentaensäure (EPA) und Docosahexaensäure (DHA) dar, welche als Strukturelemente der Phospholipide als Teil der Zellmembranen erforderlich sind. Docosahexaensäure (DHA) hat zusätzlich Bedeutung als funktioneller Bestandteil im Nervengewebe und in den Photorezeptoren der Netzhaut des Auges. Schließlich beruht die Bedeutung der Eicosapentaensäure (EPA) und Docosahexaensäure (DHA) auf ihrer Rolle als Vorstufen für die regulatorisch wirksame Eicosanoide. Unter diesem Begriff werden Prostaglandine, Prostacycline, Thromboxane und Leukotriene subsummiert. Je nach ihrer Herkunft aus Eicosapentaensäure (EPA) oder Arachidonsäure unterscheiden sich die Eicosanoide in ihrer Wirkung deutlich. So tragen die aus Eicosapentaensäure (EPA) im Gegensatz zu den aus Arachidonsäure gebildeten Thromboxane und Leukotriene dazu bei, entzündliche Prozesse zu hemmen, die Neigung zu Thrombosen zu verringern und die Fließeigenschaft des Blutes zu verbessern.Fish oil, especially Ω-3 fatty acids are known to improve the function of the immune system, rheumatic complaints and to counteract skin disorders and the onset of atherosclerosis to prevent or slow down. Ω-3 fatty acids, like Ω-6 fatty acids, are important starting materials for the Formation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which as structural elements of the phospholipids as part the cell membranes are required. Docosahexaenoic acid (DHA) has in addition Meaning as a functional component in the nerve tissue and in the photoreceptors the retina of the eye. After all the importance of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is based on their role as precursors for the regulatory eicosanoids. Be under this term Subsumed prostaglandins, prostacyclins, thromboxanes and leukotrienes. Depending on their origin may differ from eicosapentaenoic acid (EPA) or arachidonic acid the effect of the eicosanoids is clear. That's how they wear out eicosapentaenoic acid (EPA) in contrast to the thromboxane formed from arachidonic acid and Leukotriene contributes to inflammatory Inhibit processes, reduce the tendency to thrombosis and the flow characteristic to improve the blood.
Zimtextrakt wird als Karminativum bei krampfartigen Beschwerden im Darmbereich verwendet. Jüngst hat man festgestellt, dass der regelmäßige Verzehr von Zimt im Rahmen unterstützender diätetischer Maßnahmen (Diätplan) günstige Wirkungen auf den Zuckerstoffwechsel haben kann.cinnamon extract is used as a carminative for spasmodic complaints in the intestinal area used. Recently It has been found that regular consumption of cinnamon in the frame supportive dietetic activities (Diet) favorable May have effects on the sugar metabolism.
Eine medizinische Anwendung finden die Spurenelemente Kupfer und Zink in Form von Kupferoxid und Zinkoxid.A The trace elements copper and zinc are used medicinally in the form of copper oxide and zinc oxide.
Kupfer erfüllt im menschlichen Körper eine Reihe von Aufgaben: Es ist an der Bildung der roten Blutkörperchen beteiligt und spielt eine Rolle für die Funktion des zentralen Nervensystems sowie beim Pigmentstoffwechsel.copper Fulfills in the human body A number of tasks: It is the formation of red blood cells involved and plays a role in the function of the central Nervous system and pigment metabolism.
Zink findet sich in höheren Konzentrationen in den roten Blutkörperchen, in den Augen, in der Haut und in den Haaren, sowie in der Prostata und in der Leber. Zudem ist Zink Co-faktor zahlreicher Enzymsysteme, und spielt eine Rolle im Vitamin A-, im Kohlenhydrat- und im Lipidstoffwechsel. Ferner ist Zink essentiell für die Funktion verschiedener Hormone, wie z.B. Insulin, den Schilddrüsenhormonen, Sexualhormonen und den Wachstumshormonen. Auch im Stoffwechsel von Nukleinsäuren und Proteinen (Eiweißen) erfüllt Zink wichtige Aufgaben. So dient es beispielsweise der Stabilisierung der DNA- und der RNA-Struktur, ist aber auch ein Bestandteil von Schlüsselenzymen der Nukleinsäuresynthese (z.B. DNA-Polymerasen). Zink ist am Zellwachstum und an der Zelldifferenzierung beteiligt. Für eine funktionierende Immunabwehr wird ebenfalls Zink benötigt, und zwar für die zelluläre und die humorale Immunantwort, sowie für die T-Zelldifferenzierung.zinc is found in higher Concentrations in the red blood cells, in the eyes, in the skin and in the hair, as well as in the prostate and in the liver. In addition, zinc is a co-factor of numerous enzyme systems, and plays one Role in vitamin A, carbohydrate and lipid metabolism. Furthermore, zinc is essential for the function of various hormones, e.g. Insulin, the thyroid hormones, sex hormones and the growth hormones. Also in the metabolism of nucleic acids and Proteins (proteins) Fulfills Zinc important tasks. For example, it serves for stabilization the DNA and the RNA structure, but is also a component of key enzymes of nucleic acid synthesis (e.g. DNA polymerases). Zinc is involved in cell growth and cell differentiation involved. For a functioning immune defense is also needed for zinc, and though for the cellular and the humoral immune response, as well as for T-cell differentiation.
Die jeweiligen Substanzen d-α Tocopherolacetat, Zinkoxid, Kupferoxid, hochreines Fischöl, Ascorbinsäure, Carotinoide, Vitamin B Komplex, Bioflavonoide, Anthocyane und Zimtextrakt werden bereits – zum Teil in Form eines Monopräparats – bei der Behandlung und/oder Prophylaxe von Augenerkrankungen angewandt.The respective substances d-α tocopherol acetate, Zinc oxide, copper oxide, high-purity fish oil, ascorbic acid, carotenoids, Vitamin B complex, bioflavonoids, anthocyanins and cinnamon extract already - to Part in the form of a monopreparation - in the Treatment and / or prophylaxis of eye diseases applied.
Es stellte sich jedoch heraus, dass bestimmte Kombinationen der oben aufgeführten Substanzen eine besonders effiziente und vor allem individuelle Therapie entsprechend den Anforderungen der zu behandelnden Augenerkrankung bereitstellen.It However, it turned out that certain combinations of the above listed Substances a particularly efficient and above all individual therapy according to the requirements of the eye disease to be treated provide.
Aufgabe der Erfindung ist es somit individuelle, maßgeschneiderte Kombinationen zur Behandlung und/oder Prophylaxe von Augenerkrankungen, wie (altersbedingte) Makuladegeneration (AMD), Glaukom (grüner Star), Katarakt (grauer Star), diabetische Rethinopathie und trockenes Auge, bereitzustellen.task The invention thus provides individual, tailor-made combinations for the treatment and / or prophylaxis of eye diseases, such as (age-related) Macular degeneration (AMD), glaucoma (cataract), cataract (gray Star), diabetic retinopathy and dry eye.
Aufgabe der Erfindung ist es ferner einen effektiven Schutz der Makula vor Ausbildung einer postoperativen Makuladegeneration, hervorgerufen durch Linsenentfernung, wie z.B. bei einer Katarakt-Operation durch prä- und postoperative Gabe von Lutein und/oder Zeaxanthin bereitzustellen.The object of the invention is also an effective protection of the macula before training a To provide post-operative macular degeneration, caused by lens removal, such as in a cataract surgery by pre- and postoperative administration of lutein and / or zeaxanthin.
Erfindungsgemäß werden neue Kombinationen zur gleichzeitigen oder sequentiellen oralen Verabreichung umfassend mehrere Komponenten in Form eines Arzneimittels, Diätetikums, Nahrungs- oder Nahrungsergänzungsmittels, wobei die Komponenten aus Dosierungseinheiten ausgewählt werden, die d-α Tocopherolacetat, Zinkoxid, Kupferoxid, hochreines Fischöl, Ascorbinsäure, Carotinoiden, Vitamin B Komplex, Bioflavonoide, Anthocyane und Zimtextrakt enthalten, bereitgestellt.According to the invention new combinations for simultaneous or sequential oral Administration comprising a plurality of components in the form of a drug, dietetic, Food or dietary supplement, wherein the components are selected from dosage units which d-α tocopherol acetate, Zinc oxide, copper oxide, high-purity fish oil, ascorbic acid, carotenoids, Vitamin B complex, bioflavonoids, anthocyanins and cinnamon extract, provided.
Kombination aus Vitamin C, Vitamin E, ß-Carotin, Zinkoxid und Kupferoxid führten zu einem verringertem Fortschreiten der altersbedingten Maculadegeneration (Arch. Ophthalmol. 2001, 119: 1417–1436). Ferner wurde die Wirksamkeit einer Kombination aus Lutein, verschiedenen Antioxidantien und Nährstoffen auf das Fortschreiten der atrophen altersbedingten Maculadegeneration in einer randomisierten placebokontrollierten Doppelblindstudie evaluiert (Optometry, Volume 75, No.4; April 2004). In einer weiteren randomisierten, kontrollierten Studie wurde die Wirkung von ß-Carotin in Kombination mit Vitamin C, Vitamin E und Zink hinsichtlich des Risikos an altersbedingter Makuladegenertation zu erkranken, untersucht.combination from vitamin C, vitamin E, beta-carotene, Zinc oxide and copper oxide resulted to a reduced progression of age-related macular degeneration (Arch. Ophthalmol. 2001, 119: 1417-1436). Furthermore, the effectiveness was a combination of lutein, various antioxidants and nutrients on the progression of atrophic age-related macular degeneration in a randomized placebo-controlled double-blind study evaluated (Optometry, Volume 75, No.4, April 2004). In another randomized controlled trial was the effect of ß-carotene in combination with Vitamin C, Vitamin E and Zinc regarding the Risk of developing age-related macular degeneration.
Die durchgeführten Studien liefern jedoch keinen sicheren Beleg für die suffiziente medikamentöse Therapie der altersbedingten Makuladegeneration, wie ein Artikel in der „AVP-Arzneiverordnung in der Praxis" bestätigt (Ausgabe 4, Band 30, November 2003).The conducted However, studies do not provide any reliable evidence for sufficient drug therapy age-related macular degeneration, as an article in the "AVP Drug Regulation in practice "(edition 4, Vol. 30, November 2003).
Gegenüber dem Stand der Technik hat sich nun herausgestellt, dass die erfindungsgemäßen Kombinationen aus den Dosierungseinheiten, die d-α Tocopherolacetat, Zinkoxid, Kupferoxid, hochreines Fischöl, Ascorbinsäure, Carotinoide, Vitamin B Komplex, Bioflavonoide, Anthocyane und Zimtextrakt enthalten, eine effiziente Therapie zur Behandlung der oben aufgeführten Erkrankungen bereitstellen. Überraschenderweise erwiesen sich die erfindungsgemäßen Kombinationen, die als „Basis-Komponenten" die Dosierungseinheiten A, B und C umfassen, als besonders wirksam:
- Erfindungsgemäß soll die Dosierungseinheit A d-α Tocopherolacetat, Zinkoxid, Kupferoxid,
- die Dosiereinheit B hochreines Fischöl umfassend Ω-3-Fettsäuren, die Eicosanpentaensäure und Docosanhexaensäure enthalten, und
- die Dosierungseinheit C Ascorbinsäure, umfassen.
- According to the invention, the dosage unit A d-α tocopherol acetate, zinc oxide, copper oxide,
- the dosing unit B high-purity fish oil comprising Ω-3 fatty acids containing eicosane pentaenoic acid and docosanhexaenoic acid, and
- the dosage unit C ascorbic acid.
Eine derartige Kombination mit den oben definierten Basiskomponenten werden im Stand der Technik nicht vorgeschlagen.A Such combination with the basic components defined above are not proposed in the prior art.
Die potenzierte Wirkung der erfindungsgemäßen Kombinationen mit den Dosierungseinheiten A, B und C als Basiskomponenten, ist vermutlich auf den Gehalt an hochreinem Fischöl, der Ω-3-Fettsäuren und insbesondere der Eicosanpentaensäure und Docosanhexaensäure zurückzuführen: Ω-3-Fettsäuren sind wichtige Bestandteile der Zellmembranen, die jede Zelle umgeben und schützen. Sie sorgen für die Stabilität und die Flüssigkeitsversorgung der Membranen, vor allem im Bereich der Retina und der Augen. Die Docosanhexaensäure ist in den Photorezeptoren der Netzhaut des Auges angesiedelt. Als Vorstufen der Eicosanoide tragen die Eicosanpentaensäure und Docosanhexaensäure zudem dazu bei, entzündliche Prozesse durch Bildung von Thromboxane und Leukotriene zu hemmen und die Fließeigenschaft des Blutes zu verbessern. Ferner wird durch die Eicosapentaensäure EPA die Umwandlung von Arachidonsäure zu den entzündungsfördernden Eicosanoiden vermindert. Diese antiphlogistische Wirkung der Eicosapentaensäure und Docosapentaensäure wird durch die Anwesenheit der Vitamine d-α Tocopherolacetat und Ascorbinsäure in unerwarteter Weise potenziert, so dass nun eine effiziente medikamentöse Therapie bereitgestellt wird, die in die pathologischen Prozesse im Bereich des Augenhintergrundes, wie dem Untergang von retinalem Pigmentepithel aber auch der Zellproliferation, Abhebung des retinalen Pigmentepithels, sowie dem Einsprossen von Aderhautkapillaren und der Ausbildung fibrovasculärer Membranen, eingreift.The potentiated effect of the combinations according to the invention with the dosage units A, B and C as base components is probably due to the content of high purity Fish oil, the Ω-3 fatty acids and in particular eicosapentaenoic acid and docosanhexaenoic acid attributed to: Ω-3 fatty acids important components of the cell membranes that surround each cell and protect. They take care of that stability and the fluid supply of the membranes, especially in the area of the retina and the eyes. The docosahexaenoic acid is located in the photoreceptors of the retina of the eye. As precursors the eicosanoids also carry eicosanpentaenoic acid and docosanhexaenoic acid in addition, inflammatory Inhibit processes by formation of thromboxanes and leukotrienes and the flow property to improve the blood. Furthermore, the eicosapentaenoic acid EPA the conversion of arachidonic acid to the pro-inflammatory eicosanoids reduced. This antiphlogistic effect of eicosapentaenoic acid and docosapentaenoic acid is by the presence of vitamins d-α tocopherol acetate and ascorbic acid in unexpected ways potentiated, so now an efficient drug therapy is provided in the pathological processes in the field of the fundus, such as the demise of retinal pigment epithelium but also cell proliferation, withdrawal of the retinal pigment epithelium, and the sprouting of choroid capillaries and training fibrovasculärer Membranes, intervenes.
Die erfindungsgemäßen Kombinationen zur gleichzeitigen oder sequentiellen oralen Verabreichung umfassen als Komponenten die Dosierungseinheiten A, B, C und gegebenenfalls eine oder mehrere Komponenten ausgewählt aus den Dosierungseinheiten D, E, F, G, H und I. Die Dosierungseinheiten sind wie folgt definiert.The combinations according to the invention for simultaneous or sequential oral administration as components, the dosage units A, B, C and optionally one or more components selected from the dosage units D, E, F, G, H and I. The dosage units are defined as follows.
Die Dosierungseinheit A umfasst:
- d-α Tocopherolacetat
- Zinkoxid
- Kupferoxid.
- d-α tocopherol acetate
- zinc oxide
- Copper oxide.
Die Dosierungseinheit B umfasst:
- hochreines Fischöl umfassend Ω-3-Fettsäuren, die Eicosanpentaensäure und
- Docosanhexaensäure enthalten.
- high-purity fish oil comprising omega-3 fatty acids, eicosapentaenoic acid and
- Docosanhexaenoic acid.
Die Dosierungseinheit C umfasst:
- Ascorbinsäure.
- Ascorbic acid.
Die Dosierungseinheit D umfasst:
- Carotinoide, enthaltend Lutein und Zeaxanthin,
- Zink Oxid,
- Kupfer Oxid.
- Carotenoids containing lutein and zeaxanthin,
- Zinc oxide,
- Copper oxide.
Die Dosierungseinheit E umfasst:
- Vitamin B Komplex, enthaltend Riboflavin und Cobalmin.
- Vitamin B complex containing riboflavin and cobalamin.
Die Dosierungseinheit F umfasst:
- Carotinoide, enthaltend Lutein und Zeaxanthin.
- Carotenoids containing lutein and zeaxanthin.
Die Dosierungseinheit G umfasst:
- Carotinoide, enthaltend Lycopin.
- Carotenoids containing lycopene.
Die Dosierungseinheit H umfasst:
- Bioflavonoide und Anthocyane, wobei die Bioflavonoide und Anthocyane aus Heidelbeere, Holunder und Rotweintraube bereitgestellt werden.
- Bioflavonoids and anthocyanins, the bioflavonoids and anthocyanins being provided from blueberry, elderberry and red wine grape.
Die Dosierungseinheit I umfasst:
- Zimtextrakt als wässrigen Auszug.
- Cinnamon extract as aqueous extract.
Zusätzlich können die erfindungsgemäßen Dosierungseinheiten A, B, C, D, E, F, G, H und I Vitamine, Mineralstoffe, Aminosäuren, Spurenelementen, Coenzyme und Cofaktoren, sowie deren Salze oder Komplexe davon umfassen.In addition, the Dosage units according to the invention A, B, C, D, E, F, G, H and I vitamins, minerals, amino acids, trace elements, Coenzymes and cofactors, and their salts or complexes thereof include.
Die Vitamine können aus den Vitaminen A, B, C, D, E, H und K ausgewählt werden.The Vitamins can from the vitamins A, B, C, D, E, H and K.
Die Aminosäuren können aus Glycin, L-Alanin, L-Serin, L-Threonin, L-Valin, L-Leucin, L-Isoleucin, L-Asparaginsäure, L-Asparagin, L-Glutaminsäure, L-Glutamin, L-Arginin, L-Lysin, L-Hydroxylysin, L-Ornithin, L-Citrullin, L-Cystein, L-Cystin, L-Methionin, L-Thyrosin, L-Phenylalanin, L-Thryptophan, L-Histidin, L-Prolin und L-Hydroxyprolin ausgewählt werden.The amino acids can from glycine, L-alanine, L-serine, L-threonine, L-valine, L-leucine, L-isoleucine, L-aspartic acid, L-asparagine, L-glutamic acid, L-glutamine, L-arginine, L-lysine, L-hydroxylysine, L-ornithine, L-citrulline, L-cysteine, L-cystine, L-methionine, L-tyrosine, L-phenylalanine, L-thryptophan, L-histidine, L-proline and L-hydroxyproline.
Die Mineralstoffe können aus Natrium, Kalium, Magnesium, Calcium, Phosphor und Chlorid ausgewählt werden.The Minerals can be selected from sodium, potassium, magnesium, calcium, phosphorus and chloride.
Die Spurenelemente können aus Eisen, Jod, Fluorid, Zink, Kupfer, Mangan, Selen, Chrom und Molybdän ausgewählt werden.The Trace elements can of iron, iodine, fluoride, zinc, copper, manganese, selenium, chromium and molybdenum selected become.
Die Coenzyme und Cofakoren können aus Coenzym Q10, Adenosintriphosphat, Cytidintriphosphat, Guanosintriphosphat, Uridintriphosphat, Biotin, Coenzym A, Methylcobalamin, Liponsäure, Phyllohydrochinon, Pyridoxalphosphat, Retinylphosphat, Tetrahydrofolsäure, Thiaminpyrophosphat, Flavin-Adenin-Dinucleotid (FAD), Flavin-Mono-Nucleotid (FMN), Nicotinamid-Adenin-Dinucleotid (NAD) und Nicotinamid-Adenin-Dinucleotidphosphat (NADP) ausgewählt werden.The coenzymes and cofacors can be prepared from coenzyme Q 10 , adenosine triphosphate, cytidine triphosphate, guanosine triphosphate, uridine triphosphate, biotin, coenzyme A, methylcobalamin, lipoic acid, phyllohydroquinone, pyridoxal phosphate, retinyl phosphate, tetrahydrofolic acid, thiamine pyrophosphate, flavin adenine dinucleotide (FAD), flavin mono- Nucleotide (FMN), nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP).
Die Dosierungseinheiten A, B, C, D, E, F, G, H und I können in Form eines Arzneimittels, Diätetikums, Nahrungs- oder Nahrungsergänzungsmittels vorliegen.The Dosage units A, B, C, D, E, F, G, H and I can in Form of a drug, dietetics, Food or dietary supplement.
Die Dosierungseinheiten A, B, C, D, E, F, G, H und I können in Form von Kapseln, Tabletten, Dragees, Granulaten, Kautabletten, Kaugummi oder Ampullen bereitgestellt werden.The Dosage units A, B, C, D, E, F, G, H and I can in Form of capsules, tablets, dragees, granules, chewable tablets, Chewing gum or ampoules are provided.
Die Dosierungseinheiten A, B, C, D, E, F, G, H und I können zudem Formulierungshilfsstoffe wie Füllmittel (Träger), Sprengmittel, Bindemittel, Fließregulierungsmittel, Gleitmittel, Emulgatoren, Solubilisatoren, Benetzer, Entschäumer, Viskositäts- und Konsistenzbeeinflusser, Gelbildner, Lösungsmittel, Lösungsvermittler, Sorptionsmittel, Weichmacher, Trennmittel, Feuchthaltemittel, Adsorptionsmittel, Resorptionsbeschleuniger, Filmbildner, Süßungsmittel wie zum Beispiel Zucker, Zuckeraustauschstoffe und künstliche Süßstoffe, Säuerungsmittel, Aromastoffe, Farbstoffe, Antioxidantien, Synergisten, Konservierungsmittel, Geschmackskorrigentien und Färbemittel umfassen.The Dosage units A, B, C, D, E, F, G, H and I can also Formulation aids such as fillers (Carrier), Disintegrants, binders, flow regulators, Lubricants, emulsifiers, solubilizers, wetting agents, defoamers, viscosity and Consistency influencer, gelling agent, solvent, solubilizer, Sorbents, plasticizers, release agents, humectants, adsorbents, absorption accelerators, Film former, sweetener such as sugar, sugar substitutes and artificial sweeteners, acidifiers, Flavorings, Colorants, Antioxidants, Synergists, Preservatives, Taste Correctives and Colorants include.
Weitere pharmazeutisch verträgliche Hilfsstoffe, welche dem Fachmann bekannt sind, sind z.B. in Remington's Pharmaceutical Science, 15. Ausgabe, Mack Publishing Co., New Jersey (1991) beschrieben.Further pharmaceutically acceptable Adjuvants known to those skilled in the art are e.g. in Remington's Pharmaceutical Science, 15th Edition, Mack Publishing Co., New Jersey (1991).
Die erfindungsgemäßen Kombinationen der Dosierungseinheiten A, B, C, D, E, F, G, H und I eignen sich zur Behandlung von Augenerkrankungen, wie (altersbedingte) Makuladegeneration (AMD), Glaukom (grüner Star), Katarakt (grauer Star), diabetische Rethinopathie und trockenes Auge. Ferner eignet sich erfindungsgemäß die prä- und postoperative Gabe von Lutein und/oder Zeaxanthin zum Schutz der Makula vor Ausbildung einer postoperativen Makuladegeneration, hervorgerufen durch Linsenentfernung, wie z.B. bei einer Katarakt-Operation.The combinations according to the invention the dosage units A, B, C, D, E, F, G, H and I are suitable for the treatment of eye diseases, such as (age-related) macular degeneration (AMD), glaucoma (greener Cataract), diabetic retinopathy and dry Eye. Furthermore, according to the invention, the pre- and postoperative administration of Lutein and / or zeaxanthin to protect the macula from training a postoperative macular degeneration caused by lens removal, such as. in a cataract surgery.
Bevorzugte Ausführungsbeispiele sind nahestehend angegeben:
- a) Bevorzugte erfindungsgemäße Kombinationen Die erfindungsgemäße Kombination umfasst als Komponenten die Dosierungseinheiten A, B, C und gegebenenfalls eine oder mehrere Komponenten ausgewählt aus den Dosierungseinheiten D, E, F, G, H und I. Die erfindungsgemäße Kombination umfasst als Komponenten die Dosierungseinheiten A, B, C und D. Die erfindungsgemäße Kombination umfasst als Komponenten die Dosierungseinheiten A, B, C, D und E. Die erfindungsgemäße Kombination umfasst als Komponenten die Dosierungseinheiten A, B, C, D, E, G und H. Die erfindungsgemäße Kombination umfasst als Komponenten die Dosierungseinheiten A, B, C, D, E, G, H und I. Die erfindungsgemäße Kombination umfasst als Komponenten die Dosierungseinheiten A, B, C, F und gegebenenfalls die Dosierungseinheit E. Die erfindungsgemäße Kombination umfasst als Komponenten die Dosierungseinheiten A, B, C, E, G, H und gegebenenfalls eine oder mehrere Komponenten ausgewählt aus den Dosierungseinheiten F und I.
- b) Bevorzugte Dosierungsbereiche der Dosierungseinheiten A, B, C, D, E, F, G, H und I Die Dosierungseinheit A umfasst: 120 bis 268 mg d-α Tocopherolacetat 26,66 bis 40 mg Zinkoxid 0,6 bis 1,2 mg Kupferoxid. Die Dosierungseinheit B umfasst: 1500 bis 2500 mg hochreines Fischöl, umfassend 900 bis 1500 mg Ω-3-Fettsäuren, die 700 bis 1000 mg Eicosanpentaensäure und 220 bis 300 mg Docosanhexaensäure enthalten. Die Dosierungseinheit C umfasst: 225 bis 500 mg Ascorbinsäure. die Dosierungseinheit D umfasst: 6,3 bis 12,6 mg Carotinoide, enthaltend 6 bis 12 mg Lutein und 0,3 bis 0,6 mg Zeaxanthin, 26,66 bis 40 mg Zinkoxid 0,6 bis 1,2 mg Kupferoxid. Die Dosierungseinheit E umfasst: Vitamin B Komplex, enthaltend 1,5 bis 2 mg Riboflavin und 6 bis 9 μg Cobalmin; Die Dosierungseinheit F umfasst: 6,3 bis 12,6 mg Carotinoide, enthaltend 6 bis 12 mg Lutein und 0,3 bis 0,6 mg Zeaxanthin. Die Dosierungseinheit G umfasst: 10 bis 30 mg Carotinoide, enthaltend 10 bis 30 mg Lycopin. Die Dosierungseinheit H umfasst: 40 bis 80 mg Bioflavonoide und 20 bis 35 mg Anthocyane, wobei die Bioflavonoide und Anthocyane aus Heidelbeere, Holunder und Rotweintraube bereitgestellt werden. Die Dosierungseinheit I umfasst: 1500 bis 3000 mg Zimtextrakt als wässrigen Auszug.
- c) Bevorzugte Dosierungen der Dosierungseinheiten A, B, C, D, E, F, G, H und I Dosierungseinheit A: 134 mg d-α Tocopherolacetat 26,66 mg Zinkoxid 666 μg Kupferoxid; Dosierungseinheit B: 1670 mg hochreines Fischöl, umfassend 1000 mg Ω-3-Fettsäuren, die 750 mg Eicosanpentaensäure und 250 mg Docosanhexaensäure enthalten. Dosierungseinheit C: 500 mg Ascorbinsäure Dosierungseinheit D 10,5 mg Carotinoide, enthaltend 10 mg Lutein und 0,5 mg Zeaxanthin, 26,66 mg Zinkoxid 666 μg Kupferoxid; Dosierungseinheit E Vitamin B Komplex, enthaltend 2 mg Riboflavin und 9 μg Cobalmin. Dosierungseinheit F 10,5 mg Carotinoide, enthaltend 10 mg Lutein und 0,5 mg Zeaxanthin. Dosierungseinheit G 15 mg Carotinoide, enthaltend 15 mg Lycopin. Dosierungseinheit H 50 mg Bioflavonoide und 25 mg Anthocyane, wobei die Bioflavonoide und Anthocyane aus Heidelbeere, Holunder und Rotweintraube bereitgestellt werden. Dosierungseinheit I 2000 mg Zimtextrakt als wässrigen Auszug.
- d) Darreichungsform Bevorzugte Darreichungsform der erfindungsgemäßen Kombinationen sind Kapseln, Tabletten, Dragees, Granulate und Kautabletten.
- e) Anwedungsbereiche Bevorzugt eignen sich die erfindungsgemäßen Kombinationen zur Behandlung von altersbedingter Makuladegeneration, diabetischer Retinopathie, Glaukom, trockenem Auge. Ferner eignet sich erfindungsgemäß die prä- und postoperative Gabe von Lutein und/oder Zeaxanthin zum Schutz der Makula vor Ausbildung einer postoperativen Makuladegeneration, hervorgerufen durch Linsenentfernung, wie z.B. bei einer Katarakt-Operation .
- a) Preferred combinations according to the invention The combination according to the invention comprises as components the dosage units A, B, C and optionally one or more components selected from the dosage units D, E, F, G, H and I. The combination according to the invention comprises the dosage units A as components, B, C and D. The combination according to the invention comprises as components the dosage units A, B, C, D and E. The combination according to the invention comprises as components the dosage units A, B, C, D, E, G and H. The combination according to the invention comprises as components the dosage units A, B, C, D, E, G, H and I. The combination according to the invention comprises as components the dosage units A, B, C, F. and optionally the dosage unit E. The combination according to the invention comprises as components the dosage units A, B, C, E, G, H and optionally one or more components selected from the dosage units F and I.
- b) Preferred dosage ranges of dosage units A, B, C, D, E, F, G, H and I. Dosage unit A comprises: 120 to 268 mg d-α tocopherol acetate 26.66 to 40 mg zinc oxide 0.6 to 1.2 mg of copper oxide. Dosage unit B comprises: 1500 to 2500 mg of high purity fish oil comprising 900 to 1500 mg of omega-3 fatty acids containing 700 to 1000 mg of eicosapentaenoic acid and 220 to 300 mg of docosanhexaenoic acid. The dosage unit C comprises: 225 to 500 mg of ascorbic acid. dosage unit D comprises: 6.3 to 12.6 mg carotenoids containing 6 to 12 mg lutein and 0.3 to 0.6 mg zeaxanthin, 26.66 to 40 mg zinc oxide 0.6 to 1.2 mg copper oxide. The dosage unit E comprises: Vitamin B complex containing 1.5 to 2 mg of riboflavin and 6 to 9 μg of cobalamin; The dosage unit F comprises: 6.3 to 12.6 mg carotenoids containing 6 to 12 mg lutein and 0.3 to 0.6 mg zeaxanthin. Dosage unit G comprises: 10 to 30 mg carotenoids containing 10 to 30 mg lycopene. The dosage unit H comprises: 40 to 80 mg of bioflavonoids and 20 to 35 mg of anthocyanins, the bioflavonoids and anthocyanins being provided from blueberry, elderberry and red wine grape. The dosage unit I comprises: 1500 to 3000 mg of cinnamon extract as aqueous extract.
- c) Preferred dosages of the dosage units A, B, C, D, E, F, G, H and I Dosage unit A: 134 mg d-α tocopherol acetate 26.66 mg zinc oxide 666 μg copper oxide; Dosage Unit B: 1670 mg of high purity fish oil, containing 1000 mg Ω-3 fatty acids containing 750 mg eicosanpentaenoic acid and 250 mg docosanhexaenoic acid. Dosage unit C: 500 mg ascorbic acid Dosage unit D 10.5 mg carotenoids containing 10 mg lutein and 0.5 mg zeaxanthin, 26.66 mg zinc oxide 666 μg copper oxide; Dosage unit E Vitamin B complex containing 2 mg riboflavin and 9 μg cobalmine. Dosage unit F 10.5 mg carotenoids containing 10 mg lutein and 0.5 mg zeaxanthin. Dosage unit G 15 mg carotenoids containing 15 mg lycopene. Dosage unit H 50 mg bioflavonoids and 25 mg anthocyanins, the bioflavonoids and anthocyanins being made from blueberry, elderberry and red wine grape. Dosage unit I 2000 mg cinnamon extract as aqueous extract.
- d) Dosage Form Preferred dosage form of the combinations according to the invention are capsules, tablets, dragees, granules and chewable tablets.
- e) Applications The combinations according to the invention are preferably suitable for the treatment of age-related macular degeneration, diabetic retinopathy, glaucoma, dry eye. Furthermore, according to the invention, the pre- and postoperative administration of lutein and / or zeaxanthin to protect the macula before the formation of a postoperative macular degeneration, caused by lens removal, such as in a cataract operation.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE202005012984U DE202005012984U1 (en) | 2005-08-17 | 2005-08-17 | Oral combination, useful in the treatment and/or prophylaxis of eye diseases e.g. glaucoma, comprises one or more dosage units comprising e.g. zinc oxide; highly purified fish oil; ascorbic acid and optionally carotenoid, cinnamon |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE202005012984U DE202005012984U1 (en) | 2005-08-17 | 2005-08-17 | Oral combination, useful in the treatment and/or prophylaxis of eye diseases e.g. glaucoma, comprises one or more dosage units comprising e.g. zinc oxide; highly purified fish oil; ascorbic acid and optionally carotenoid, cinnamon |
Publications (1)
Publication Number | Publication Date |
---|---|
DE202005012984U1 true DE202005012984U1 (en) | 2005-11-24 |
Family
ID=35455524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE202005012984U Expired - Lifetime DE202005012984U1 (en) | 2005-08-17 | 2005-08-17 | Oral combination, useful in the treatment and/or prophylaxis of eye diseases e.g. glaucoma, comprises one or more dosage units comprising e.g. zinc oxide; highly purified fish oil; ascorbic acid and optionally carotenoid, cinnamon |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE202005012984U1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932520A1 (en) * | 2006-12-15 | 2008-06-18 | Novartis AG | Nutritional supplement composition for treatment of ocular diseases |
EP1932521A1 (en) * | 2006-12-15 | 2008-06-18 | Novartis AG | Nutritional supplement composition for treatment of ocular diseases |
WO2009015879A1 (en) * | 2007-07-31 | 2009-02-05 | Fresenius Kabi Deutschland Gmbh | Cachexia prevention supplement |
WO2009098186A1 (en) * | 2008-02-04 | 2009-08-13 | Novartis Ag | Organic compounds |
WO2010074940A1 (en) * | 2008-12-23 | 2010-07-01 | Alcon Research, Ltd. | Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response |
WO2011060492A1 (en) * | 2009-11-18 | 2011-05-26 | The University Of Sydney | Combination for treating metabolic disorders |
-
2005
- 2005-08-17 DE DE202005012984U patent/DE202005012984U1/en not_active Expired - Lifetime
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932520A1 (en) * | 2006-12-15 | 2008-06-18 | Novartis AG | Nutritional supplement composition for treatment of ocular diseases |
EP1932521A1 (en) * | 2006-12-15 | 2008-06-18 | Novartis AG | Nutritional supplement composition for treatment of ocular diseases |
WO2008071803A1 (en) * | 2006-12-15 | 2008-06-19 | Novartis Ag | Nutritional supplement composition for treatment of ocular diseases |
WO2008071775A1 (en) * | 2006-12-15 | 2008-06-19 | Novartis Ag | Nutritional supplement composition for treatment of ocular diseases |
WO2009015879A1 (en) * | 2007-07-31 | 2009-02-05 | Fresenius Kabi Deutschland Gmbh | Cachexia prevention supplement |
EP2025248A1 (en) * | 2007-07-31 | 2009-02-18 | Fresenius Kabi Deutschland GmbH | Cachexia prevention supplement |
WO2009098186A1 (en) * | 2008-02-04 | 2009-08-13 | Novartis Ag | Organic compounds |
WO2010074940A1 (en) * | 2008-12-23 | 2010-07-01 | Alcon Research, Ltd. | Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response |
WO2011060492A1 (en) * | 2009-11-18 | 2011-05-26 | The University Of Sydney | Combination for treating metabolic disorders |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60201824T2 (en) | FOOD SUPPLEMENT FOR THE TREATMENT OF MACULAR AGENCY | |
DE69907010T2 (en) | COMPOSITION CONTAINING UBICHINONE SUITABLE FOR PROMOTING THE INCREASED INTRAMITOCHONDRIAL TRANSPORTATION OF UBICHINONES AND METHODS OF USE THEREOF | |
EP1471898B1 (en) | Lutein/zeaxanthin for glare protection | |
DE60217103T2 (en) | REINFORCED EFFECT OF MULTIPLE UNSATURATED FATTY ACIDS | |
US7842722B2 (en) | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision | |
KR20090089473A (en) | Nutritional supplement composition for treatment of ocular diseases | |
EP0804239B1 (en) | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof | |
EP1317264B1 (en) | Combination of lipoic acids and conjugated acids for treating diabetic disorders | |
WO1996017584A2 (en) | Combined preparation for stimulating hair growth and optionally nail growth and skin regeneration and for preventing or combatting hair loss | |
EP0755633B1 (en) | Two phases preparation | |
KR20090089474A (en) | Nutritional supplement composition for treatment of ocular diseases | |
KR20080078066A (en) | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision | |
DE202005012984U1 (en) | Oral combination, useful in the treatment and/or prophylaxis of eye diseases e.g. glaucoma, comprises one or more dosage units comprising e.g. zinc oxide; highly purified fish oil; ascorbic acid and optionally carotenoid, cinnamon | |
JP2008533075A (en) | Vitamin mixture | |
CA2979112A1 (en) | Eye health composition | |
DE202008009883U1 (en) | Compositions for maintaining, enhancing, improving or supporting eye health | |
DE10326822A1 (en) | Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids | |
RU2698396C1 (en) | Pharmaceutical composition for parenteral drop introduction | |
WO2006042728A2 (en) | Use of stable ammonium liponate salts for the treatment of diabetic and other disorders | |
EP2269649A2 (en) | Compositions containing a capillary active system with application-related differentiability, and the use thereof | |
JP2004323486A (en) | Prophylactic and therapeutic eye lotion for retina and/or uvea disease | |
EP0820770A2 (en) | Pharmaceutical compositions for the treatment fo neuropathies containing a lipid-soluble thiamine and an antioxidant | |
AT13410U1 (en) | Use of a ubiquinone component and a combined preparation to improve female fertility | |
AT17461U1 (en) | Dietary supplement with maquiberry extract | |
EP3415144A1 (en) | Combination therapy for treating a macular degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R207 | Utility model specification |
Effective date: 20051229 |
|
R156 | Lapse of ip right after 3 years |
Effective date: 20090303 |